Posted by Michael Wonder on 07 Oct 2020
NICE terminates yet another appraisal
7 October 2020 - 9 of the last 20 published technology appraisals have been terminated.
NICE is unable to make a recommendation on alpelisib (Piqray) with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer because Novartis did not provide an evidence submission.
NICE will review this decision if Novartis decides to make a submission.
